Comparative Pharmacology
Head-to-head clinical analysis: SYNALAR HP versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALAR HP versus TRIACORT.
SYNALAR-HP vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
10-20 mg orally once daily
None Documented
None Documented
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid